Study of Efficacy and Safety of Voretigene Neparvovec in Japanese Patients With Biallelic RPE65 Mutation-associated Retinal Dystrophy

NCT04516369 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

4

Enrollment

INDUSTRY

Sponsor class

Conditions

Biallelic RPE65 Mutation-associated Retinal Dystrophy

Interventions

GENETIC: voretigene neparvovec

Sponsor

Novartis Pharmaceuticals